reports
Atea Pharmaceuticals Inc: 1 director
A director at Atea Pharmaceuticals Inc sold 359,606 shares at 2.846USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Vaxart Provides Merger Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen. “We are committed to creating significant value for all our shareholders as evidenced by the amended terms of the merger that were recently announced,” said Wou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.